A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers

R. S. Choung, N. J. Talley, J. Peterson, Michael Camilleri, D. Burton, W. S. Harmsen, A. R. Zinsmeister

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Itopride, a dopamine D2 antagonist and acetylcholinesterase inhibitor, significantly improved symptoms in patients with functional dyspepsia in one phase II randomized trial. However, the mechanisms by which itopride may improve symptoms are unknown. We aimed to compare the effects of two doses of itopride and placebo on gastric volumes, gastric emptying, small bowel transit and satiation in female and male healthy volunteers. Randomized, double-blind, placebo-controlled study evaluated gastric function before and after 7 days of itopride 100 mg (n = 16) or 200 mg (n = 15) or placebo (n = 15) t.i.d. Validated methods were used to study gastric accommodation (single photon emission computed tomography), gastric emptying and orocecal transit and satiation postnutrient challenge. The three arms were comparable with regard to age, gender and body mass index. There were no statistically significant effects of itopride on gastric emptying, orocecal transit, fasting gastric volume, maximum tolerated volume or aggregate symptom score with nutrient drink challenge. Postprandial (PP) change in gastric volume differed in the three groups (P = 0.019): 625[±28 (SEM)], 555(±26) and 512(±33) in placebo, itopride 100 and 200 mg groups, respectively. In healthy subjects, itopride reduced total PP gastric volume without accelerating gastric emptying or significantly altering gastric motor and sensory function in healthy individuals.

Original languageEnglish (US)
Pages (from-to)180-187
Number of pages8
JournalNeurogastroenterology and Motility
Volume19
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Stomach
Healthy Volunteers
Randomized Controlled Trials
Placebos
Gastric Emptying
Satiation
Dyspepsia
Cholinesterase Inhibitors
itopride
Single-Photon Emission-Computed Tomography
Fasting
Body Mass Index
Food

Keywords

  • Accommodation
  • Itopride
  • Motility
  • Stomach

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology
  • Neuroscience(all)

Cite this

A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers. / Choung, R. S.; Talley, N. J.; Peterson, J.; Camilleri, Michael; Burton, D.; Harmsen, W. S.; Zinsmeister, A. R.

In: Neurogastroenterology and Motility, Vol. 19, No. 3, 03.2007, p. 180-187.

Research output: Contribution to journalArticle

@article{b6fade22c3a34898ab3c9594a28a33b6,
title = "A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers",
abstract = "Itopride, a dopamine D2 antagonist and acetylcholinesterase inhibitor, significantly improved symptoms in patients with functional dyspepsia in one phase II randomized trial. However, the mechanisms by which itopride may improve symptoms are unknown. We aimed to compare the effects of two doses of itopride and placebo on gastric volumes, gastric emptying, small bowel transit and satiation in female and male healthy volunteers. Randomized, double-blind, placebo-controlled study evaluated gastric function before and after 7 days of itopride 100 mg (n = 16) or 200 mg (n = 15) or placebo (n = 15) t.i.d. Validated methods were used to study gastric accommodation (single photon emission computed tomography), gastric emptying and orocecal transit and satiation postnutrient challenge. The three arms were comparable with regard to age, gender and body mass index. There were no statistically significant effects of itopride on gastric emptying, orocecal transit, fasting gastric volume, maximum tolerated volume or aggregate symptom score with nutrient drink challenge. Postprandial (PP) change in gastric volume differed in the three groups (P = 0.019): 625[±28 (SEM)], 555(±26) and 512(±33) in placebo, itopride 100 and 200 mg groups, respectively. In healthy subjects, itopride reduced total PP gastric volume without accelerating gastric emptying or significantly altering gastric motor and sensory function in healthy individuals.",
keywords = "Accommodation, Itopride, Motility, Stomach",
author = "Choung, {R. S.} and Talley, {N. J.} and J. Peterson and Michael Camilleri and D. Burton and Harmsen, {W. S.} and Zinsmeister, {A. R.}",
year = "2007",
month = "3",
doi = "10.1111/j.1365-2982.2006.00869.x",
language = "English (US)",
volume = "19",
pages = "180--187",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers

AU - Choung, R. S.

AU - Talley, N. J.

AU - Peterson, J.

AU - Camilleri, Michael

AU - Burton, D.

AU - Harmsen, W. S.

AU - Zinsmeister, A. R.

PY - 2007/3

Y1 - 2007/3

N2 - Itopride, a dopamine D2 antagonist and acetylcholinesterase inhibitor, significantly improved symptoms in patients with functional dyspepsia in one phase II randomized trial. However, the mechanisms by which itopride may improve symptoms are unknown. We aimed to compare the effects of two doses of itopride and placebo on gastric volumes, gastric emptying, small bowel transit and satiation in female and male healthy volunteers. Randomized, double-blind, placebo-controlled study evaluated gastric function before and after 7 days of itopride 100 mg (n = 16) or 200 mg (n = 15) or placebo (n = 15) t.i.d. Validated methods were used to study gastric accommodation (single photon emission computed tomography), gastric emptying and orocecal transit and satiation postnutrient challenge. The three arms were comparable with regard to age, gender and body mass index. There were no statistically significant effects of itopride on gastric emptying, orocecal transit, fasting gastric volume, maximum tolerated volume or aggregate symptom score with nutrient drink challenge. Postprandial (PP) change in gastric volume differed in the three groups (P = 0.019): 625[±28 (SEM)], 555(±26) and 512(±33) in placebo, itopride 100 and 200 mg groups, respectively. In healthy subjects, itopride reduced total PP gastric volume without accelerating gastric emptying or significantly altering gastric motor and sensory function in healthy individuals.

AB - Itopride, a dopamine D2 antagonist and acetylcholinesterase inhibitor, significantly improved symptoms in patients with functional dyspepsia in one phase II randomized trial. However, the mechanisms by which itopride may improve symptoms are unknown. We aimed to compare the effects of two doses of itopride and placebo on gastric volumes, gastric emptying, small bowel transit and satiation in female and male healthy volunteers. Randomized, double-blind, placebo-controlled study evaluated gastric function before and after 7 days of itopride 100 mg (n = 16) or 200 mg (n = 15) or placebo (n = 15) t.i.d. Validated methods were used to study gastric accommodation (single photon emission computed tomography), gastric emptying and orocecal transit and satiation postnutrient challenge. The three arms were comparable with regard to age, gender and body mass index. There were no statistically significant effects of itopride on gastric emptying, orocecal transit, fasting gastric volume, maximum tolerated volume or aggregate symptom score with nutrient drink challenge. Postprandial (PP) change in gastric volume differed in the three groups (P = 0.019): 625[±28 (SEM)], 555(±26) and 512(±33) in placebo, itopride 100 and 200 mg groups, respectively. In healthy subjects, itopride reduced total PP gastric volume without accelerating gastric emptying or significantly altering gastric motor and sensory function in healthy individuals.

KW - Accommodation

KW - Itopride

KW - Motility

KW - Stomach

UR - http://www.scopus.com/inward/record.url?scp=33846916642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846916642&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2982.2006.00869.x

DO - 10.1111/j.1365-2982.2006.00869.x

M3 - Article

C2 - 17300287

AN - SCOPUS:33846916642

VL - 19

SP - 180

EP - 187

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

IS - 3

ER -